Meningococcal Conjugate Vaccine MCV4

Known as: MCV4, Meningococcal Conjugate Vaccine MCV-4, Meningococcal Polysaccharide (Serogroups A, C, Y and W-135) Diphtheria Toxoid Conjugated Vaccine 
A conjugate vaccine of meningococcal polysaccharide used for active immunization against invasive meningococcal disease caused by Neisseria… (More)
National Institutes of Health

Related topics

Related topics

1 relation
Vaccines, Conjugate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Text4Health: impact of text message reminder-recalls for pediatric and adolescent immunizations.
OBJECTIVES We conducted 2 studies to determine the impact of text message immunization reminder-recalls in an urban, low-income… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
2012
2012
Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children.
BACKGROUND Human immunodeficiency virus (HIV)-infected children are at increased risk of meningococcal infection and poor… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
2012
2012
Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus.
OBJECTIVE To compare the immunogenicity of 1 vs 2 doses of meningococcal polysaccharide conjugate vaccine (MCV4) in youth… (More)
Is this relevant?
2011
2011
HPV vaccine decision making in pediatric primary care: a semi-structured interview study
BACKGROUND Despite national recommendations, as of 2009 human papillomavirus (HPV) vaccination rates were low with < 30% of… (More)
  • table 1
  • table 2
Is this relevant?
2010
2010
Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era--United States, 2000-2005.
BACKGROUND A quadrivalent meningococcal conjugate vaccine (MCV4) was licensed in the United States in 2005; no serogroup B… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2010
2010
Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents.
The persistence of human bactericidal activity (hSBA) responses in adolescents was assessed 22 months after vaccination with one… (More)
Is this relevant?
2010
2010
Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age.
BACKGROUND Routine administration of quadrivalent meningococcal conjugate vaccine to adolescents and certain high risk groups is… (More)
Is this relevant?
2008
2008
Report from the Advisory Committee on Immunization Practices (ACIP): decision not to recommend routine vaccination of all children aged 2-10 years with quadrivalent meningococcal conjugate vaccine…
  • MMWR. Morbidity and mortality weekly report
  • 2008
At its February 2008 meeting, the Advisory Committee on Immunization Practices (ACIP) decided not to recommend routine… (More)
Is this relevant?
2007
2007
Meningococcal conjugate vaccine uptake, measured by Michigan's immunization registry.
PURPOSE To describe the uptake of meningococcal conjugate vaccine (MCV4) in Michigan adolescents following its approval in… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
In January 2005, a tetravalent meningococcal polysaccharide-protein conjugate vaccine ([MCV4] Menactra, manufactured by Sanofi… (More)
Is this relevant?